Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin eye drops for recurrent bacterial posterior blepharitis
jRCT1071230068Recruiting
- Sponsor
- Ryohei Nejima
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of azithromycin in meibomianitis and blepharitis, sponsored by Ryohei Nejima. Primary endpoint: Recovery rate at 14 days after start of eye drops. Started Sep 2023; status: recruiting.
02
Drugs
azithromycin
03
Conditions
meibomianitisblepharitis
Beyond the preview
Go deeper on jRCT1071230068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071230068.